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Abstract
Background: We evaluated the associations among angiotensin-converting enzyme (ACE) gene insertion/deletion
(I/D) polymorphism, ACE activity and post-myocardial infarction (MI) left ventricular dysfunction and acute heart
failure (AHF) early after presentation with MI with ST-segment elevation (STEMI).
Methods: A total of 556 patients with STEMI treated by primary PCI (421 patients without AHF and 135 patients
with AHF) were the study population. The activity of BNP, NT-ProBNP and ACE were measured at hospital
admission and 24 h after MI onset. Left ventricular angiography was done before PCI; echocardiography was
undertaken between the third and fifth day after MI.
Results: In comparison with the II genotypes group, the DD/ID group had a higher level of ACE activity upon
hospital admission (p < 0.001). We found a significantly higher level of ACE activity in patients with moderate LV
dysfunction (EF 40-54%) in comparison both with patients with preserved LV function (EF ≥55%) and with patients
with severe LV dysfunction (p = 0.028). A non-significant trend towards a higher incidence of mild AHF (22.1% vs.
16.02%, p = 0,093), a significantly higher value of end-systolic volume (ESV/BSA) (30.0 ± 12.3 vs. 28.5 ± 13.0; p < 0.05)
and lower EF (50.2 ± 11.1 vs. 52.7 ± 11.7; p < 0.05) in the DD/ID genotypes group was noted. Even after multiple
adjustments according to multivariate models, the EF for the DD/ID group remained significantly lower (p = 0,033).
The DD/ID genotypes were associated with a significantly higher risk of EF <45% (OR 2.04 [95% CI 1.28; 3.25]).
Conclusions: These results suggest that the I/D polymorphism of ACE is associated with the development of LV
dysfunction in the acute phase after STEMI. We demonstrated for the first time an association of the low ACE
activity with the severe LV dysfunction, although patients with moderate LV dysfunction had higher level ACE
activity than patients with preserved LV function.
Background
The angiotensin-converting enzyme (ACE) is a mem-
brane-bound, zinc metalloendopeptidase involved in the
metabolism of many small peptides, particularly in acti-
vating angiotensin I to angiotensin II and inactivating
bradykinin via the kallikrein-kininogen system. The
enzyme is expressed on the surface of cells in many tis-
sues, and its richest source is the lung. ACE also circu-
lates in a soluble form produced by proteolytic cleavage
of the extracellular portion from endothelial cells.
Angiotensin II increases contraction of vascular smooth
muscle cells. It also affects proliferation of smooth mus-
cle cells; adhesion and diapedesis of monocytes through
stimulation of expression of several adhesion molecules
and chemoattractants; and the adhesion and aggregation
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fibrogenic responses during MI, thus promoting scar
formation. On the other hand Angiotensin II-induced
reactive oxygen species production may further damage
myocardium in the border zones and enlarge infarct size
[1]. The ACE gene is located on chromosome 17q23. In
t h ei n t r o n1 6o ft h eA C Eg e n ei sa nI / Dp o l y m o r p h i s m
which contains an insertion (I) and deletion (D)–the
presence or absence of 287 bp Alu repeat [2,3]. Homo-
zygotes for the deletion allele (DD) have serum ACE
levels higher (on average) as those homozygous for the
insertion allele (II), whereas heterozygotes (ID) have
intermediate levels [2-4]. The genetic effect accounts for
28%-47% of the total variance of serum ACE [2,3]. Also
cardiac ACE activity is higher in subjects with the DD
genotype [4]. Early treatment by ACE inhibitors after
myocardial infarction (MI) decreases adverse remodeling
of the left ventricle, the incidence of heart failure, and
mortality [5-11]. Several smaller studies found an
increased risk of left ventricular enlargement or remo-
deling among individuals with the DD/ID genotype after
MI [12-16], others were negative, but in the presence of
ACEI therapy [17].
However recently published results detected new single-
nucleotid polymorphisms associated with low mRNA
expression and with adverse cardiovascular outcomes [18].
Based on these results, we hypothesized a higher activ-
ity of ACE in the acute stage of ST segment elevation
myocardial infarction (STEMI) in patients with DD/ID
genotypes compared with individuals homozygous for
the insertion allele (II). We investigated if the ACE I/D
polymorphism and levels of ACE activity in the acute
period after STEMI treated with primary PCI were asso-
ciated with post-MI left ventricular dysfunction and evi-
dence of acute heart failure.
Methods
Study population
Written informed consent was obtained from all sub-
jects before participation in the study. The study proto-
col complied with the Declaration of Helsinki, and was
approved by the local Ethics Committee of Faculty Hos-
pital Brno and by the Ethics Committee of the Masaryk
University in Brno (Brno, Czech Republic).
From November 2005 to October 2008, 913 patients
with STEMI were referred for primary percutaneous
coronary intervention (PCI). They were admitted to the
Coronary Care Unit (CCU) of Internal Cardiological
Department of Faculty Hospital Brno. The diagnosis of
STEMI was based on symptoms consistent with MI in
conjuction with appropriate changes on electrocardiogra-
phy (ECG) (ST-segment elevation or new left bundle
branch block (LBBB)) and elevation in the levels of mar-
kers of myocardial necrosis (troponin I). Time from the
onset of chest pain until primary PCI was <12 h. Standard
therapy, including ACE inhibitors, beta-blockers and sta-
tins, was given as soon as possible after primary PCI.
Exclusion criteria were: age >80 years (n = 112); known or
newly diagnosed malignancy; inflammatory diesease or
connective-tissue diesease; known previous LV dysfunc-
tion; estimated life expectancy <12 months (n = 48); refu-
sal to sign the consent inform or non-compliance (n = 74);
geographic reasons (distance from the place of residence
to the hospital of >100 km without the possibility of fol-
low-up; n = 35). In total, 51 patients were not included
because of technical and organizational problems. Geno-
types were not obtained for 37 patients. In total, 556 con-
secutive patients with STEMI were included in the present
study. A control population of 200 healthy subjects (age,
48-80 years; median, 65 years; 76.5% male) without a his-
tory of CAD or heart failure were evaluated by specialized
cardiologists in the Brno region. The diagnosis of acute
heart failure was assessed according to clinical signs upon
hospital admission and/or during hospitalization (Killip
class I-IV). Mild acute heart failure was defined as pul-
monary congestion with wet rales in the lower half of the
lung fields or S3 gallop. The study population was divided
into two groups according to ACE I/D polymorphism
(DD/ID group and II group).
Laboratory methods
Samples of venous blood for analyses of the activity of B-
type natriuretic peptide (BNP), N-terminal pro B-type
natriuretic peptide (NT-ProBNP) and ACE were drawn
immediately upon hospital admission before primary PCI
(sample 1). Blood samples were drawn again at 24 h after
the onset of chest pain (sample 2). Samples were centri-
fuged within 20 min in a refrigerated centrifuge, and the
plasma and serum stored at -80°C. Standard biochemical
and hematological blood tests were done immediately at
hospital admission before primary PCI and 24 h after the
onset of chest pain (including Troponin-I ADSV, Abbott
Laboratories, Abbott Park, USA). BNP was analyzed
using the AxSYM BNP-Microparticle Enzyme Immu-
noassay (Abbott Laboratories, Abbott Park, USA). NT-
ProBNP was analyzed using the Cobas E411 NT-proBNP
Imunoassay Kit (Roche Diagnostics, Indianapolis). The
activity of ACE was analysed using ACE kinetic assay
(Bühlmann laboratories AG, Switzerland).
Echocardiography assessment
Echocardiography was carried out during the index
admission (between the third and fifth day after MI
onset). Left ventricular end-systolic volume (LVESV), left
ventricular end-diastolic volume (LVEDV), and left ven-
tricular ejection fraction (LVEF) were estimated using the
bi-planar Simpson’s rule from apical two- and four-
chamber views (93.8% and 94.6% of all measurements in
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the Teicholz formula. Echocardiography was assessed by
two operators using Vivid 7 or Vivid i (GE Vingmed
Ultrasound).
Invasive measurement
Ejection fraction (EF) was determined by LV angiogra-
phy (5-F pigtail catheter) before primary PCI. A diseased
coronary vessel was defined as having ≥50% reduction of
the intraluminal diameter of any of the coronary arteries
(left main, left anterior descending, left circumflex, right
coronary) or the main branches with a diameter ≥2.0
mm. Significant left main artery stenosis was classified
as “two-vessel disease”.
Genetic analysis
DNA was extracted from peripheral leukocytes using the
standard proteinase K technique. Genotyping of the inser-
tion/deletion polymorphism in angiotensin I-converting
enzyme (I/D ACE) was done using polymerase chain reac-
tion (PCR) methods according to the method of Rigat and
Shanmugam [19]. DNA amplification was undertaken in a
volume of 25 μL containing 50 ng genomic DNA with 1
unit Taq polymerase (MBI Ferments, USA). Using gel
electrophoresis, PCR products were distinguished at 1.5%
Serva with ethidium bromide in UV light as a 190 bp frag-
ment in the absence of an Alu repeat insertion and a 490
bp fragment in the presence of the insertion (genotypes
described as II-490 bp, ID-490+190 bp, and DD-190 bp).
Blind samples were used to control the reliability of
genotyping.
Statistical analyses
Summary statistics for categorical variables are shown as
frequencies. Normally distributed continuous variables
are shown as mean and SD or median and 5-95
th per-
centile range for variables with non-normal distribution.
Within all groups, the distributions of genotypes and
consistency of genotype frequencies with the Hardy-
Weinberg equilibrium were tested using the c
2 test on a
contingency table of observed versus predicted genotype
frequencies. The allelic frequences were compared by
Fisher’s exact test. The point estimates of the risk, the
odds ratio (OR) and 95% confidence interval (CI) based
on logistic regression were estimated and supplemented
by their significance (Ward’st e s t ) .C h a n g e sw i t h i n
groups were analyzed by Wilcoxon signed-ranks test,
and differences between two groups were analyzed by
the Mann-Whitney U test. Correlations were analyzed
by Spearman’s rank order correlation coefficient. A
probability value of a < 0.05 was considered to indicate
significance. Multivariate linear regression was applied
for adjustment of markers of LV dysfunction on the
influence of other variables. Preselection of variables
based on univariate linear regression and a backward
stepwise algorithm were used for the definition of these
models. The power of tests and sample size were evalu-
ated by EpiInfo6. Statistical analyses were undertaken
using Stat View version 8.0 (SAS Institute Incorporated,
2008), SPSS 18.0.3 (IBM, Corporation 2010) and STA-
TISTICA 8.0 (StatSoft, Inc. 2008).
Results
Genotypes were obtained for 556 patients of the study
group. Demographic characteristics and the clinical
background of patients are shown in Table 1. All
patients and control subjects were Caucasian. Patients
with DD/ID genotypes were more often diabetic (p <
0.05) with higher stress glucose level during admission
(p < 0.05). Previous treatment (Table 1), treatment in
the course of hospitalization and at the time of hospital
discharge with ACE inhibitors, beta-blockers and statins
were comparable between genotype groups (ACE inhibi-
tors and/or AT II blockers 94.7%, beta-blockers 96.6%,
statins 96.3%). The median time from the onset of chest
pain to admission to the CCU was 170 min and the
median “door-to-balloon” time was 63 min. The times
were comparable between genotype groups (p = NS).
Significant differences were not observed in the distri-
butions of ACE genotypes and/or allele frequences
between patients with acute MI (DD 29.5%, ID 41.2%, II
29.3%; I 46.5%, D 53.5%) and healthy controls (DD
28.1%, ID 50.7%, II 21.2%; D 50.1%, I 49.9%) (p = NS).
In comparison with the II genotype group, the DD
genotype group had a higher level of ACE activity
upon admission, while ID genotype group had an
intermediate level of ACE activity (medians of ACE
activities of DD vs ID vs II genotype groups were 36.7
U/L vs 31.4 U/L vs 24.1 U/L, p < 0.001). We found a
significantly higher level of ACE activity for patients
with moderate LV dysfunction (EF 40-54%; n = 301;
described by median and 5-95
th percentile (30.9 U/L
(10.2-65.5)) in comparison both with patients with pre-
served LV function (EF ≥55%; n = 185; 28.5 U/L (8.2-
60.4)) and in patients with severe LV dysfunction (EF
≤40%; n = 70; level of ACE activity 27.8 U/L (5.4-
62.6)) (p = 0.028). Using multivariate linear regression,
only age, previous treatment with ACE inhibitors or
AT1-antagonists and I/D polymorphism were detected
as variables with a statistically significant influence on
ACE activity (25% of variability of ACE activity was
explained by a given model; 4.9% of the total variability
of ACE activity could be explained by ACE gene I/D
polymorphism in this model).
Total hospital mortality was 3.54% with no difference
a m o n gg r o u p s( D D3 . 6 5 % ,I D3 . 0 6 % ,I I4 . 8 7 % ) .I nt o t a l ,
27.0% of patients had signs and symptoms of acute
heart failure AHF (Killip class II and above) during
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towards a higher incidence of mild AHF for the DD/ID
genotypes group (Table 1). Hemodynamic and echocar-
diographic measurements are shown in Table 2. In the
case of DD/ID genotypes carriers, we found a signifi-
cantly higher value of ESV/BSA and significantly lower
EF. We created a multivariate model and we found that
EF is dependent only on the previous myocardial infarc-
tion, creatinine, infarct related artery (RIA), number of
affected arteries and the time from the oncet of chest
pain till the patency of infarct-related artery (Table 3).
The EF and other parameters of LV dysfunction were
multiple adjusted according to the multivariate models
(Table 3) and the values were compared between DD/
ID and II genotypes carriers. Only the adjusted EF for
DD/ID group was still significantly lower (adjusted EF
described by median and 5-95
th percentile for DD/ID
genotype group 50.5% (49.5; 51.4) vs II genotype group
52.0% (50.4; 53.6) (p = 0.033)). The DD/ID group had
a significantly higher risk of EF <45% before hospital
discharge (OR (95% CI) 2.04 (1.28; 3.25) (p = 0.003)),
a similar result was found for DD/ID subgroup of
patients without diabetes mellitus (OR (95% CI) 2.17
(1.25; 3.80) (p = 0.006).
Discussion
ACE gene polymorphism and prognosis after MI
Samani [20] concluded that I/D polymorphism did not
significantly influence the risk of mortality after MI in a
group of 684 patients with MI. Yoshida [21] revealed that
the endpoints of the study (cardiac death, reccurent MI or
unstable angina) were significantly associated with the
ACE ID polymorphism (RR = 4.49), and that the DD/ID
genotype was associated with a higher occurrence of the
endpoints. Similar results were revealed by Palmer [12]. In
a study of 978 patients after MI, the DD/ID genotypes
were associated with a higher risk of mortality with an OR
of 8.03 (95% CI, 2.16-29.88; p < 0.05). In the present study,
an association of in-hospital mortality and I/D ACE poly-
morphism was not observed. This was probably because
of the very short duration of follow-up (this work explored
only the time of hospitalization) and fewer subjects.
Table 1 Baseline characteristics of patients, treatment, and neurohumoral measurements in the ACE genotype group
All patients DD/ID genotype II genotype p*
N = 556 N = 393 N = 163 DD/ID vs. II
Age (years) 62.7 ± 10.5 62.7 ± 10.3 62.6 ± 10.8 0.972
Males 74.6 75.1 73.6 0.722
Weight (kg) 83.9 ± 14.0 84.2 ± 14.1 83.1 ± 13.9 0.330
BMI (kg/m
2) 28.1 ± 3.9 28.1 ± 4.0 27.9 ± 3.7 0.893
BP systolic (mmHg) 135.6 ± 27.0 135.3 ± 27.2 136.1 ± 26.5 0.315
BP diastolic (mmHg) 74.7 ± 14.4 74.5 ± 14.2 75.1 ± 15.0 0.302
Heart rate (per min) 73.0 (52.0-108.0) 73.0 (52.0; 107.6) 72.0 (50.4; 109.4) 0.941
Time delay (min) 238.0 (123.0-650.0) 245.0 (122.1; 667.0) 228.0 (121.6; 590.2) 0.282
AHF 27.0 28.2 23.9 0.296
Mild AHF (%) 20.3 22.1 16.0 0.093
Smokers
† (%) 54.7 54.7 54. 6 0.982
Diabetes (%) 27.9 30.5 21.5 0.027
Hypertension (%) 57.4 58.3 55.2 0.508
ACE inhibitors (%) 25.4 24.4 27.6 0.435
AT II (%) 7.0 7.4 6.1 0.597
Beta-blockers (%) 27.2 27.7 25.8 0.634
Statins (%) 16.5 16.5 16.6 0.994
Glucose (mmol/L) 8.1 (5.5-17.3) 8.2 (5.7; 17.4) 7.7 (5.3; 16.7) 0.006
Troponin I (ng/mL) 50.2 (3.1-182.1) 48.9 (3.2; 186.5) 52.2 (2.4; 181.3) 0.940
BNP at hospital admission (pg/mL) 66.3 (15.0-489.7) 66.2 (15.0; 504.1) 68.0 (15.0; 491.0) 0.314
BNP after 24 h (pg/ml) 275.2 (68.2-890.0) 286.7 (68.1; 892.9) 269.3 (70.0; 1145.5) 0.955
NT-ProBNP at hospital admission (pg/mL) 223.0 (33.0-4 233.0) 230.0 (33.0; 4512.0) 183.0 (28.1; 5350.2) 0.435
NT-ProBNP after 24 h (pg/mL) 1946.0
(370.0-11 542.0)
2019.0
(384.1; 10197.9)
1805.0
(355.4; 15008.4)
0.432
ACE activity (IU/L) 30.6 (4.1-68.3) 33.6 (4.1; 70.6) 24.1 (4.4; 63.8) < 0.001
Continuous variables are presented as mean, SD, median, 5-95 percentiles, and categorized as percentage proportion. * The Mann-Whitney U test or chi-square
test were used for testing differencies between genotype groups
† smokers = current smokers and ex-smokers; BMI - Body mass index; Time delay = time
between onset of chest pain and ballon dilatation
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left ventricle function
Circulating ACE probably originates from vascular
endothelial cells. Higher levels of plasma ACE were
found for the DD/ID genotypes of healthy subjects [3]
as well as of patients with CAD [22,23]. At the same
time Danser [4] explored ACE activity in the cardiac tis-
sue of subjects who died of non-cardiac disorders, and
the highest levels were in subjects with the DD geno-
type. An elevated activity of ACE during the acute phase
of STEMI in association with I/D polymorphism ACE
has not been documented. We demonstrated for the
first time a clear association of a higher activity of ACE
in DD genotype group in comparison with II group in
acute phase of STEMI, while the ID genotype group had
an intermediate level of ACE activity. There is a lack of
data concerning the ACE activity and its interaction
with AHF and LV dysfunction. Cambien [22] indicated
that a higher level of ACE in plasma could be a risk fac-
tor for MI independent of the I/D polymorphism. Nakai
[24] concluded that the deletion polymorphism of the
ACE gene was associated with a higher activity of ACE
in serum and carried an increased risk of CAD in Japa-
nese subjects. Other results were presented by Garde-
mann [23], who concluded that increased ACE activity
was not a risk factor for CAD or MI. A completely new
look Johnson [18] brought at 2009, he detected three
promotor single-nucleotide polymorphisms (SNPs) of
the ACE gene connected with reduced ACE mRNA
expression in cardiac tissue. These identified SNPs
(rs7213516 and rs4290) were tested in a large cohort of
1032 hypertonics and they were associated with adverse
cardiovascular outcomes, largely attributable to nonfatal
Table 2 Invasive and echocardiographic measurements
All
patients
DD/ID
genotype
II
genotype
p*
N = 556 N = 393 N = 163 DD/ID vs.
II
DCV 1.89 ± 0.80 1.92 ± 0.80 1.83 ± 0.80 0.236
IRA - LM 2 (0.4%) 2 (0.5%) 0 0.893
IRA - LAD (%) 256
(46.0%)
183 (46.6%) 73 (44.8%) 0.772
IRA - RCx (%) 74 (13.3%) 51 (13.0%) 23 (14.1%) 0.825
IRA - RCA (%) 224
(40.3%)
157 (39.9%) 67 (41.1%) 0.875
Initial TIMI
0-1 380
(68.3%)
270 (68.7%) 110
(67.5%)
0.050
2 91 (16.4%) 71 (18.1%) 20 (12.3%)
3 85 (15.3%) 52 (13.2%) 33 (20.2%)
TIMI after PCI
0-1 13 (2.3%) 10 (2.5%) 3 (1.8%) 0.830
2 51 (9.2%) 37 (9.4%) 14 (8.6%)
3 492
(88.5%)
346 (88.0%) 146
(89.6%)
EF
(angiography)
49.4 ± 12.2 49.3 ± 21.4 49.7 ± 12.0 0.644
EDV/BSA (mL/
m
2)
62.4 ± 17.0 62.1 ± 16.9 63.2 ± 17.5 0.583
ESV/BSA (mL/
m
2)
29.6 ± 12.5 30.0 ± 12.3 28.5 ± 13.0 0.049
EF (echo) (%) 50.9 ± 11.3 50.2 ± 11.1 52.7 ± 11.7 0.006
Continuous variables are presented as mean, SD, median, 5-95 percentiles,
and categorized as percentage proportion. *The Mann-Whitney U test or chi-
square test were used for testing differencies between genotype groups
DCV: Diseased coronary vessels; IRA: infarct-related artery; LM: left main; LAD:
left anterior descending coronary artery; RCx: ramus cirumflexus; RCA: right
coronary artery; EF: ejection fraction of the left ventricle; EDV: end-diastolic
volume; ESV: end-systolic volume; BSA: Body surface area.
Table 3 Multivariate models for adjusting of parameters of left ventricle dysfunction
Ejection fraction
(echo)
Ejection fraction
(angiography)
EDV/
BSA
ESV/
BSA1
BNP1 BNP2 NT-pro
BNP1
NT-pro
BNP2
Age - - - - < 0.001 < 0.001 < 0.001 < 0.001
Sex (Women) - - 0.001 0.003 0.004 < 0.001 < 0.001 < 0.001
BMI - - - - - - 0.017 -
Diabetes mellitus 0.336 - 0.140 0.067 - - - -
Previous
instability
- - - - 0.037 - < 0.001 0.001
Infarction < 0.001 0.001 < 0.001 < 0.001 - - - -
Betablocators - - - - < 0.001 - 0.002 -
Creatinine3 0.004 < 0.001 - - < 0.001 < 0.001 < 0.001 < 0.001
IRA - RIA < 0.001 < 0.001 - 0.010 - < 0.001 - < 0.001
DCV 0.001 - - 0.007 0.260 0.005 0.011 0.002
Time delay (min) 0.003 < 0.001 - - < 0.001 0.069 < 0.001 0.002
R
2 17.3% 18.6% 5.7% 9.0% 26.9% 31.6% 42.0% 42.7%
Statistical significance of relationship was analyzed by means of linear regression; parameters ESV/BSA, BNP and NT-proBNP were log transformed prior to
analysis. R
2 stands for variability explained by given model.
EDV: end-diastolic volume; ESV: end-systolic volume; BSA: Body surface area; BMI: Body mass index; IRA: infarct-related artery; DCV: Diseased coronary vessels
Parenica et al. BMC Cardiovascular Disorders 2010, 10:60
http://www.biomedcentral.com/1471-2261/10/60
Page 5 of 8MI in African Americans. The high allele frequency was
found in African Americans (16%), but low in Hispanics
(4%) and very low in Caucasians (< 1%). We do not sup-
pose these SNPs play a relevant role in our study popula-
tion according to low allele frequency in Caucasians only
1 or 2 subjects could be expected. But very important is
an idea that very low level of ACE activity could be harm-
full. So far the higher levels of ACE activity associated
with DD/ID genotypes of ACE were connected with
worse prognosis [24], but existing results were not con-
sistent [23,24]. For the first time our results suggest a
non-linear type of a dependence of ACE activity and
adverse cardiac outcomes. As we showed, higher levels of
ACE activity were associated with moderate LV dysfunc-
tion (EF 40-54%), but lower levels of ACE activity were
found in patients with preserved LV function (EF ≥ 55%)
as well as in patients with severe LV dysfunction (EF <
40%). The results of Johnson study [18] and the Valsartan
Heart Failure (Val-HeFT) trial [25] raise the possibility,
that excessive neurohormonal inhibition may contribute
to adverse outcomes in heart failure treatment.
ACE gene polymorphism and LV systolic dysfunction after
MI
Infarct size is one of the most important determinants
of the progression of the LVEDV [26]. Pinto et al. [16]
reported that enlargement of the left ventricle 12
months after an anterior MI was more pronounced in
patients with the DD genotype than in patients with the
ID or II genotypes. They did not find any differences in
the volumes of the left ventricle in the acute stage of MI
[16]. Ohmichi [15] associated the DD and ID genotypes
of the ACE gene with the progression of the left ventri-
cular end-diastolic volume index (LVEDVI) and end-
systolic volume index (LVESVI) 4 months after MI.
Multiple regression analysis revealed that the LVESVI at
echocardiography 7 ± 4 days after MI and ACE I/D
polymorphism are predictors of the increases in the
LVEDVI a LVESVI on the second echocardiogram. In a
group of 43 patients with old anteroseptal MI-treated
PCI (they were not treated by ACE inhibitors), Nagashi
[14] found a significantly higher LV end-systolic and
end-diastolic dimension in the deletion group. Ulgen
[13] proved the relationship of ACE gene polymorphism
and LV remodeling in the early period in 142 patients
with anterior MI. Echocardiographic examinations were
undertaken within 24 h of MI and on the fifth day. LV
systolic diameters, diastolic diameters and EF between
the first and second echocardiographic results were sig-
nificantly different in theD Dg r o u p .P a l m e r[ 1 2 ]
demonstrated a significantly greater LVEDV and the
increased LVESV bordered on significance when 223
DD individuals were compared with grouped ID ad II
patients (n = 572). This was not confirmed in a study by
Zee [17], which provided no evidence of an association
of the ACE I/D polymorphism with the risk of LV
remodeling post-MI in the presence of ACE-I therapy.
During the fifth day after MI, we demonstrated a signifi-
cantly greater LVESVI and worse EF for the DD/ID gen-
otypes in a homogenous group of patients with STEMI
despite treatment by primary PCI and full pharmacolo-
gical treatment (including ACE inhibitors given as soon
as possible). We consider the difference of EF between
the both genotype groups on the border of clinical sig-
n i f i c a n c e ,t h ea b s o l u t ev a l u eo ft h eE Fd i f f e r e n c ew a s
only 1.5% after adjustments for other variables. This
borderline influence of ACE polymorphism may explain
inconsistent results of previous smaller studies on the
development of left ventricular dysfunction, especially
when ACE inhibitors were administered.
ACE gene polymorphism and AHF
We did not find data in the literature concerning the
clinical signs of AHF during the acute stages of MI and
polymorphism of the ACE gene. An accurate assignation
of diagnosis of acute heart failure could be influenced in
border line by individual assessment of the subject sta-
tus. We found a non-significant trend for an association
of I/D ACE polymorphism and signs of mild AHF.
ACE gene polymorphism and BNP and NT-proBNP
BNP is a cardiac hormone that is secreted mainly from the
ventricles in response to excessive stretching of cardio-
myocytes. NT-proBNP is an inactive molecule resulting
from the cleavage of the prohormone Pro-BNP. Palmer
[12] showed that patients with the DD genotype had a sig-
nificantly higher plasma level of BNP, N-terminal BNP,
and endothelin levels within 96 h after MI than those
observed in the II/ID group. These data was in correlation
with a greater LVEDV in the DD group. In our study a sig-
nificant association between DD/ID polymorphism of the
ACE gene and BNP or NT-proBNP was not found even
after the multiple adjustments for variables significantly
influencing the level of BNP or NT-proBNP. Probably the
later assesment of BNP/NT-proBNP after MI (96 hours in
Palmer study vs 24 hours after MI onset in our study) is
likely more relevant to determine subsequent development
of left ventricular dysfunction in which the ACE poly-
morphism may participate.
Comparison with previous studies
Previous studies have not defined exactly the type of MI
(NSTEMI or STEMI) and the manner of revasculariza-
tion. Just the type and time of revascularization are cru-
cial factors for the dysfunction and remodeling of the
left ventricle and congestive heart failure. Primary PCI is
associated with a significant reduction in mortality and
reinfarction in patients with STEMI, above all in
Parenica et al. BMC Cardiovascular Disorders 2010, 10:60
http://www.biomedcentral.com/1471-2261/10/60
Page 6 of 8patients with AHF [27,28]. Several trials and studies
proved a positive influence of treatment by ACE inhibi-
tors for the progression of LV remodeling and heart fail-
ure. Although patients had full treatment of acute
coronary syndrome with STEMI–revascularization by
primary PCI (PCI was succesful in 97.5% of patients),
ACE inhibitors, beta-blockers and statins were usually
administered immediately after PCI, we found a border
interaction between I/D ACE polymorphism and signs
of LV systolic dysfunction up to 5 days after MI. For the
first time we confirmed definitely that the level of ACE
activity is influenced by I/D polymorphism in acute
stage of myocardial infarction, although only small part
of ACE activity variability may be explained by this
polymorphism. We demonstrated that the higher level
of ACE activity is associated with the development of
the moderate left ventricular dysfunction in comparison
with ACE activity in patients with preserved left ventri-
cular function. However the severe left ventricular dys-
function (EF < 40%) was associated also with low ACE
activity. These new results may help explain ambiquous
findings of previous studies.
Limitation of the study
Although our study population belongs to larger
cohorts, on which interraction between left ventricular
dysfunction and I/D polymorphism was investigated so
far, a much larger group would be better to set up. The
results brought new information about interraction
among I/D gene polymorphism, ACE activity and the
development of left ventricular dysfunction. However we
do not believe the stratification of patients according to
I/D polymorphism and ACE activity is useful in the
daily clinical practice.
Conclusion
The present study clearly demonstrated an association
between I/D gene polymorphism and the development
of LV dysfunction in the acute stage of STEMI despite
revascularization by primary PCI and early treatment
using ACE inhibitors and beta-blockers. For the first
time we confirmed definitely that the level of ACE activ-
ity is influenced by I/D polymorphism also in acute
stage of myocardial infarction. We demonstrated that
higher level of ACE activity was associated with the
development of the moderate left ventricular dysfunc-
tion in comparison with ACE activity of patients with
preserved left ventricular function, however the severe
left ventricular dysfunction (EF < 40%) was associated
with low ACE activity as well.
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